BioVersys

Swiss biopharmaceutical company BioVersys AG focuses on researching and developing small molecules that can block resistance to existing antibiotics. With the company's award-winning TRIC technology (Transcriptional Regulator Inhibitory Compound), the efficacy of established antibiotics can be restored. In this way, BioVersys addresses the high medical need for new therapies against life-threatening bacterial infections that have emerged in recent years due to bacterial strains developing resistance to existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing the efficacy and intellectual property of established drugs. Current research focuses on hospital-acquired infections and tuberculosis.